

# Influence of puerarin, paeoniflorin, and menthol on structure and barrier function of tight junctions in MDCK and MDCK-MDR1 Cells

Lin Zhang, Shouying Duao\*, Yang Lui\*\*, Chang Lqiu, Huichao, Bing Yang, Bai, Pengyue

*School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China*

## Abstract—

To find out how the drugs cross the blood-brain barrier (BBB), this study examined how puerarin, paeoniflorin, and menthol affected the structure and function of tight junctions (TJs) in MDCK and MDCK-multi-drug resistance 1 (MDR1) cells.

The cells were first treated with puerarin, paeoniflorin, and menthol. Then, they were stained with occludin, claudin-1, and F-actin using immunohistochemistry. Next, laser-scanning confocal microscopy was used to examine the cells. An epithelial voltage voltmeter was used to assess transepithelial electrical resistance (TEER), and ImageJ software was used to analyse the average optical density (AOD) of the protein immunofluorescence pictures. The results showed that tight junction proteins treated with puerarin and paeoniflorin were visible under confocal microscopy, but menthol reduced their expression. Similarly, the menthol group's AOD value was downregulated, while the control group's value was not different from the AOD values of cells treated with either puerarin or paeoniflorin, or both. After three hours, the TEER of cells that were not exposed to menthol were comparable to those of the control group, but treatment with

With a p-value less than .05, menthol considerably reduced the TEER score. And menthol's TEER-lowering effects on MDCK cells were noticed before those on MDCK-MDR1 cells. Ultimately, it seems that menthol, in contrast to puerarin and paeoniflorin, has the potential to decrease the barrier function of TJs, which in turn enhances paracellular transport and drug penetration of the blood-brain barrier.

## Introduction

Medications designed to target certain areas of the brain either do not reach those areas or do not reach enough concentrations once they do. The blood-brain barrier (BBB) governs and controls the molecular permeation between the brain's periphery and interior, and when the levels of drugs administered to the brain are inadequate, it is often due to the barrier function of the brain's capillary endothelial cells.<sup>1e4</sup> One of the best cell models to mimic the BBB in vitro is MadineDarby canine kidney epithelial (MDCK) cells or MDCK cells transfected with the human multidrug resistance 1

(MDR1) gene (MDCK-MDR1).<sup>5, 6</sup> The BBB is a barrier system that keeps the brain's internal environment steady and supports appropriate brain processes. It consists of a single layer of brain capillary endothelial cells joined by tight junctions (TJs). When it comes to molecules that go via the paracellular route, TJs are crucial for molecular permeability of the BBB. In addition to defining cell polarity by separating the apical and basolateral cell surface regions, they also serve as a barrier and fence. Upon examination under electron microscopy, transmembrane junctions (TMJs)—which include integral membrane proteins—are seen as a region of tightly connected

membranes at the apex of neighbouring cells that face the lumen. A variety of transient junction proteins, such as occludin, claudins, zona occludens protein 1 (ZO-1), and F-actin, are expressed by MDCK and MDCK-MDR1 cells because their transient junction structures are similar to those of brain capillary endothelial cells. Through their hydrophobic barrier function and intramembranous fence, TJs limit medication delivery to underlying tissues and reduce drug permeability of the blood-brain barrier (BBB). Some medications may change the structure and characteristics of transmembrane junctions (TMJs) by acting on TJ proteins to make them more permeable to the brain or to other drugs, or both. This is because TJ tightness is dictated by the protein composition of the webs of the related proteinaceous filaments (called strands). In order to create medications that target the brain and effectively cure disorders, it is crucial to research how chemicals affect TJ proteins and how they may cross the blood-brain barrier (BBB). An essential aspect of the folkloric therapeutic practice is the prescription of tongqiaosanyu, a traditional medicinal formula from China. Kudzu root (*Pueraria lobata*), white peony root (*Paeonia albiflora*), and mint (*Mentha hap-localyx* Briq.) are among the plants that make up the mix. Tongqiaosanyu is a treatment for stroke in China. The primary active ingredients have been determined to be menthol, paeoniflorin, and pierin by pharmacodynamic screening. "Puerarin (8-[beta-D-glucopyranosyl] -7-hydroxy-3-[4-hydroxyphenyl])" Traditional Chinese Medicine (TCM) has made extensive use of -4H-1-benzopyran-4-one (C<sub>21</sub>H<sub>20</sub>O<sub>9</sub>), the main isoflavone glycoside extracted from kudzu root, for the treatment of ischemic stroke and cardiovascular diseases.<sup>17</sup> with e<sup>19</sup> 5-Beta-[[Benzoyloxy] methyl] paeoniflorin 5,4-dioxacyclobuta[cd] tetrahydro-5-hydroxy-2-methyl-2,5-methano-1H-[2H] pentalen-1-alpha The monoterpene glucoside iso-lated from white peony root is known as -yl-beta-D-glucopyranoside (C<sub>23</sub>H<sub>28</sub>O<sub>11</sub>). It enhances glucose uptake and possesses neuroprotective, anti-inflammatory, anti-allergy, and antihyperglycemic properties.<sup>20</sup> The chemical formula for menthol is C<sub>10</sub>H<sub>20</sub>O, and it is a primary component of peppermint oil, which increases blood-brain barrier (BBB) permeation and has excitatory effects on the central nervous system

(CNS).<sup>21</sup> Analytical methodologies for the primary active constituents were developed in our prior examination of Tongqiaosanyu. Furthermore, we investigated the in vivo pharmacokinetic behaviour of Tongqiaosanyu, its compatibility with other medications, and several methods of administration. The processes by which puerarin crosses the blood-brain barrier (BBB) have been documented, as have its cytotoxicity and transport in MDCK and MDCK-MDR1 cells. Nevertheless, it is still not known how these chemicals paracellularly cross the blood-brain barrier (BBB), particularly how they affect protein structure and barrier function. Hence, we aimed to find out how this formula TJs worked and what part each chemical played in transport by simulating the BBB using MDCK and MDCK-MDR1 cells. Researchers looked at how these medications entered the brain and how certain medicines improved their penetration.

## Materials and methods

### Materials

Puerarin, paeoniflorin, and menthol were purchased from the National Institute for Food and Drug Control (Beijing, China). Polyester (PET) cell culture inserts and 12-well plates (12-mm diameter, 0.4-mm pore size) were obtained from Corning Life Sciences (Corning, NY, USA). Rabbit anti- occludin antibody (ab31721) was obtained from Abcam Shanghai (Shanghai, China). Mouse anti-claudin-1 antibody (2H10D10) was purchased from Invitrogen (Camarillo, CA, USA). Anti-rabbit IgG - tetramethylrhodamineisothiocyanate (TRITC) conjugate was purchased from ZSG-BIO (Beijing, China). Anti-mouse-fluoresceinisothiocyanate (FITC) conjugated antibody was purchased from Kangwei Century Biotechnology (Beijing, China). Acti-stain 488 phalloidin staining for F-actin was obtained from Cytoskeleton (Denver, CO, USA).

### Cell culture

MDCK and MDCK-MDR1 cells were generously provided by Dr. Zeng (Zhejiang University, China). Both cell lines were cultured with Dulbecco's modified Eagle's media (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco, Fremont, CA, USA), 100 U/mL penicillin, and 0.1 mg/mL streptomycin in a humidified atmosphere of 5% CO<sub>2</sub> at 37°C. The medium was replaced with fresh medium every other day until the cells reached approximately 90% confluence.

### Grouping and drug administration

In a previous study,<sup>22</sup> the cytotoxicity of puerarin, paeoni- florin, and menthol in MDCK and MDCK-MDR1 cells using 3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-azolium bro- mide (MTT) assay. Results showed puerarin, paeoniflorin, and menthol were not cytotoxic at concentration ranges of

0e0.3 mg/mL, 0e0.4 mg/mL, and 0e0.04 mg/mL, respectively. Furthermore, puerarin plus paeoniflorin (1:0.4 w/v, PP), puerarin plus menthol (1:0.5 w/v, PM), and puerarin plus paeoniflorin plus menthol (1:0.4:0.5, w/w/w, PPM) groups exhibited no cytotoxicity at concentration ranges of 0e0.2 mg/mL (paeoniflorin), 0e0.05 mg/mL (menthol), and 0e0.04 mg/mL (menthol), respectively. Based on the results of MTT assay, this study included the following six treatment groups: puerarin, paeoniflorin, and menthol (0.1 mg/mL, 0.04 mg/mL, and 0.05 mg/mL, respectively), as well as the PP group (0.1 mg/mL puerarin and 0.04 mg/mL paeoniflorin, respectively), PM group (0.1 mg/mL puerarin and 0.05 mg/mL menthol, respectively), and PPM group (0.1 mg/mL puerarin, 0.04 mg/mL paeoniflorin, and 0.05 mg/mL menthol, respectively) groups.

### Immunofluorescence microscopy

For immunocytochemical analysis, the cells were seeded on 15 mm coated glass coverslips. When cell fusion attained approximately 80e90%, the regular media were replaced with media containing the various compounds (puerarin, paeoniflorin, or menthol at 0.1 mg/mL, 0.04 mg/mL and the previously described drug combinations was measured at 30, 60, 90,120,150, and 180 min. TEER was measured immediately following drug treatment (0 min) and was set to 100%, with all the other values calculated and expressed relative to this value. Finally, TEER at each time point was compared to that of the control group and statistically analyzed.

### Data analysis and statistics

Immunofluorescence images were analyzed semi-quantitatively using ImageJ software based on the following equations:

$$\frac{\text{IntDen}}{\text{Area}} \quad (1)$$

where IntDen is the integrated optical density (IOD) of the image, Area is the region of fluorescence in the image, and AOD is the average optical density.

Percentage AOD (%) of the TJ proteins was calculated using the following equation:

$$\text{AOD}_{\text{sample}}$$

0.05 mg/mL, respectively) and the cells were further cultured for 3 h, and then fixed with cold 4% para- relative AOD (%)Z

formaldehyde for 30 min. After washing thrice for 5 min each with phosphate-buffered saline (PBS), the coverslips were incubated for 1 h with goat serum as the blocking buffer. Then, after rinsing with PBS thrice, some coverslips were incubated with polyclonal anti-occludin or monoclonal anti-claudin-1primary antibodies (1:100, each)

at 4°Covernight followed by incubation with TRITC- conjugated anti-rabbit IgG or FITC-conjugated anti-mouse IgG. Other cells were only stained with Acti-stain 488 phalloidin stain (1:150) at 25°C for 30 min. Cell nuclei were counterstained with 4', 6-diamidino-2-phenylindole (DAPI, Beijing Solarbio Science and Technology, Beijing, China). The cells were visualized using an inverted fluorescence microscope equipped with appropriate filters (Olympus, Tokyo, Japan). Images were acquired using a laser scanning confocal microscope and accompanying analysis software. Fluorescence intensity of the images was measured using ImageJ software (National Institutes of Health, Bethesda, MD, USA).

### Measurement of transepithelial electrical resistance

To investigate changes in the TJs barrier function of the MDCK and MDCK-MDR1 cells, transepithelial electrical resistance (TEER) of the monolayers was detected using the EVOM epithelial voltohmmeter (EMD Millipore, Billerica, MA, USA). Both cell types were cultured separately on0.4 mm pore size filters of 12 mm Transwellsand grown to confluence. Then, 0.5 mL and 1.5 mL of drug solution and Hank's basic salt solution (HBSS) were added to the apical (A) side and basolateral (B) side, respectively to simulate A / B transport while in a parallel experiment, B / A transport was simulated by reversing the order of the drug solution and HBSS. TEER of untreated or puerarin-, paeoniflorin-, and menthol-treated cells or those treated with where AOD<sub>sample</sub> and AOD<sub>control</sub> are the AODs of the sample and control, respectively.

Percentage TEER was calculated using the following equation:

$$\text{Relative TEER (\%)} = \frac{\text{TEER}_t}{\text{TEER}_{t_0}} \times 100 \quad (3)$$

where TEER<sub>t</sub> is the TEER value at different times and TEER<sub>t<sub>0</sub></sub> is the initial TEER value before the experiment was performed.

Results are presented as means (SD) of 3 separate par- allel experiments. Data were analyzed using a one- way analysis of variance (ANOVA), followed by Dunnett's test to determine the difference between multiple groups compared to the control group using SPSS version 17.0

software. A *P* < .05 was considered statistically significant.

## Results

### Effect of compounds on expression of TJ proteins

To determine the effects of the compounds on TJ proteins of the MDCK and MDCK-MDR1 cells, we immunohis- tochemically analyzed occludin, claudin-1, and F-actin using laser scanning confocal microscopy (Fig. 1). All three TJ proteins showed positive staining in both cell types and occludin stained red, claudin-1and F-actin stained green, and the nuclei stained blue. Both cell types had similar TJ barrier function systems.



After treatment with puerarin and paeoniflorin, the visual morphology of occludin, claudin-1, and F-actin in both kinds of cells was not difference from that of the hardly observed (Fig.

untreated cells. However, incubation with menthol, decreased the TJ proteins in both MDCK and MDCK-MDR1-cells and the morphology was (Fig. 1A, B, respectively).




Fig. 1 Effect of puerarin, paeoniflorin, and menthol on tight junction (TJ) proteins in (A) MadineDarby canine kidney epithelial (MDCK) and (B) MDCK-multi-drug resistance 1 (MDR1) cells ( $\times 600$ ). (A) Immunocytochemistry for occluding, claudin-1, and F-actin in MDCK cells with puerarin or paeoniflorin showed similar fluorescent morphology with the control group. All three proteins were decreased in MDCK cells by menthol. (B) Fluorescence intensity in MDCK-MDR1 cells with different compounds was similar to that in MDCK cells. Scale bar corresponds to 1.0  $\mu$ m.

#### Changes in AOD of TJ proteins after treatment with different compounds

Fluorescence intensity of the immunofluorescent images was semi-quantitatively analyzed. AOD values of each protein were calculated using ImageJ software and statistical analysis was conducted (Fig. 2). The control, puerarin, and paeoniflorin groups showed similar approximate relative AOD values in the MDCK and MDCK-MDR1 cells, while the menthol group was significantly different compared to

the control group ( $P < .05$ ).

### Changes in TEER of cells treated with various compounds




Fig. 2 Change in relative average optical density (AOD) of occludin, claudin-1, and F-actin in (A) MadineDarby canine kidney (MDCK) epithelial and (B) MDCK-multi-drug resistance 1 (MDR1) cells after treatment with different compounds. (A) Relative AOD values of tight junction (TJ) proteins in MDCK cells treated with puerarin or paeoniflorin showed no significant difference compared to the control group while AOD values of the menthol group were significantly reduced. (B) Relative AOD values in MDCK-MDR1 cells treated with different compounds were the same as in MDCK cells. Only menthol reduced AOD of all three proteins. Data presented as mean (SD) ( $n \geq 3$ ).  $P < .05$  compared to control group.

compounds for up to 3 h. TEER values of each group treated with the compounds for different times were statistically compared with those of the control group (Fig. 3). MDCK cells (Fig. 3A) treated with puerarin, paeoniflorin, and PP exhibited similar changes in TEER compared to the control group in the A  $\rightarrow$  B and B  $\rightarrow$  A transport processes. At

90 min, TEER of the menthol, PM, and PPM groups decreased significantly compared with that of the control group ( $P < .05$ ). In MDCK-MDR1 cells (Fig. 3B), groups not treated with menthol exhibited a steady

To determine the effects of the compounds on the function of the TJ barrier, we measured the TEER values of MDCK and MDCK-MDR1 cells after exposure to the various

TEER change similar to the control group and menthol-treated groups showed a significant decrease at 120 min ( $P < .05$ ) in both the A  $\rightarrow$  B and B  $\rightarrow$  A transport processes compared to control.

### Discussion

Use of both in vivo and in vitro methods has led to the elucidation of certain aspects of the drug transport process across the BBB. In vivo studies of the BBB provide valuable observational information and direct analysis of drug permeation processes such as drug distribution in each brain region. However, there are some limitations and shortcomings to this method including the laborious nature of the experiments, individual differences, and complicated analytical methods. Accordingly, development of in vitro models is highly desired to facilitate the clarification of the BBB permeability mechanisms. Such desired models mainly include those that would predict the associated BBB processes using computer simulation technology, parallel artificial membrane permeability assay (PAMPA), and in vitro cell culture techniques.<sup>6</sup> Cell culture is currently the favored tool for simultaneously obtaining complex and comprehensive information of passive and active transport processes. Generally, there are two types of cell culture models that are used to simulate the BBB. One consists of the “real BBB model,” which is based on primary cultures of brain capillary endothelial cells or single cell lines that may be complemented or co-cultured with astrocytes/pericytes.<sup>23,24</sup> The other type is the “surrogate BBB model,” which uses similar epithelial cells such as MDCK, MDCK-MDR1, and human colon carcinoma cell lines (Caco-2).<sup>5,25,26</sup> Among these, MDCK and MDCK-MDR1 have been recognized as the ideal models for in vitro simulation of BBB drug penetration.<sup>6,27e29</sup> They have several advantages including (1) stable source with no batch-to-batch variability, (2) convenient for routine experimental application and thus reduce labor intensity, (3) adequately and closely mimic relevant in vivo properties of the BBB, (4) ensure adequate monolayer integrity and display a proper TEER value under conventional experimental conditions, and (5) show superior P-glycoprotein (P-gp) expression and activity, particularly in MDCK-MDR1 cells transfected with the human MDR1 gene, which is a very important efflux transporter in the BBB.<sup>30e34</sup> Therefore, we chose MDCK and MDR1-MDCK cells to establish our in vitro BBB model.

Drugs cross the blood brain barrier by two main methods: transcellular and paracellular transport. In addition, numerous elements impede penetration of drugs and substances from the extra-brain region to the brain area, including the BBB morphologic characteristics (such as






Fig. 3 Change in transepithelial electrical resistance (TEER) in (a, b) MadineDarby canine kidney (MDCK) epithelial and (c, d) MDCK multi-drug resistance 1 (MDCK-MDR1) cells after treatment with different compounds. (a, b) TEER of MDCK cells gradually decreased following treatment with compounds alone or in combination with menthol. (c, d) TEER in menthol-treated MDCK-MDR1 cells similarly declined. Data presented as mean (SD) (n Z 3). PP: puerarin and paeoniflorin; PM: puerarin and menthol; PPM: puerarin, paeoniflorin and menthol groups.

existence of TJs), enzymes in the cytosol on the extra-cellular membrane, and P-glycoprotein (P-gp). For hydro-philous compounds, paracellular transport is a crucial pathway for penetrating the brain and exerting a thera-peutic effect. The physiologic function of the TJ is inseparable from paracellular transport and its barrier and fence functions are regulated by various factors.<sup>35e37</sup> Using on the simulated BBB MDCK and MDCK-MDR1 cell model, we focused on studying the mechanism of the main active constituents in the Tongqiaosanyu prescription to deter-mine their effects on the structure and barrier function of TJs.

The TJ structure is composed of various types of proteins and occludin is regarded as the primary identifying mole-cule of the TJ strands. It is a tetraspan membrane protein of approximately 60-kD, with a short intracellular curve, two extracellular annuli, and N- and C-terminals in the cytoplasmic domain.<sup>38</sup> Assembly of TJs and concomitant increase in TEER have been demonstrated to be associated with tyrosine phosphorylation of occludin, which is a phe-nomenon commonly observed after recovery from adeno-sine triphosphate (ATP) depletion or during calcium repletion.<sup>39,40</sup> Claudins have different sequences from occluding and are 18- to 27-kDtetraspan proteins with two extracellular annuli, a short N-terminus, and a C-

terminal in the cytoplasmic domain.<sup>41</sup> Claudin-1 is also considered an important strand or even the back bone of TJs.<sup>42</sup> Recent studies have shown that claudin-1 is the decisive compo-nent of TJs and possesses cell adhesion activity.<sup>43</sup> It can directly affect the regulation of paracellular transport and the selectivity of solute size. F-actin, which is one of the peripheral membrane proteins of TJs, is related to organ-elle movement, protoplasmic streaming, and intercellular junctionregulation.<sup>7,44e47</sup> Importantly, the F-actin belt can control TJ function and limit the material intake.<sup>48</sup>

Although we did not investigate all TJ protein types in MDCK and MDCK-MDR1 cells, the proteins we chose were excellent representations. We individually analyzed the immunofluorescence staining of occludin, claudin-1, and F-actin in MDCK and MDCK-MDR1 cells after treatment with puerarin, paeoniflorin, or menthol. The puerarin and paeoniflorin group did not affect the staining properties of TJ proteins. Only menthol inhibited the expression and reduced the fluorescence intensity (AOD value) of all three

kinds of TJ proteins. This characteristic of menthol indicated that it directly disrupted the structure and integrity of TJs to open the BBB barrier. These results combined with previous reports led us to infer that disruption of the configuration and integrity of TJ by menthol might be

caused by phosphorylation of TJ components, activation of protein kinases, or calcium depletion.<sup>49e52</sup>

TEER measurement has been widely applied in evaluating the integrity of the monolayer and studying the permeability of transport processes. Changes in TEER values have been directly linked to the function of the paracellular occluding barrier.<sup>53,54</sup> TEER is caused by cell-substrate contact, and if the distance of the cell-substrate is short, a high TEER value is observed. Based on this physiologic characteristic, paracellular resistance and the average cell-substrate distance can be estimated by the TEER. Paracellular resistance consists of the serial resistance of the TJs as well as lateral intercellular resistance.<sup>55</sup> Therefore, to establish the relationship between the change in TEER and the state of TJ barrier function, we used EVOM instrumentation to determine the TEER of two kinds of cells at different time points after treatment with the compounds. The results were consistent with those of immunocytochemistry, and revealed that TEER value gradually declined following treatment of cells with menthol, and values of the other groups were relatively stable during the test period. Therefore, this experiment showed that menthol is capable of weakening the BBB and enhancing paracellular transport. The mechanism of the decrease in TEER also involves  $\text{Ca}^{2+}$  influx and the  $\text{Ca}^{2+}$  chelator EGTA blocked cofilin dephosphorylation. Furthermore, the alteration may have been caused by activity variation of intrinsic membrane proteins.<sup>56</sup> For example, removal and addition of  $\text{Ca}^{2+}$  to the filter where MDCK cell layers form a monolayer may reversibly lead to their TJs opening and resealing, and the cell-substrate separation may correspondingly increase or decrease.<sup>57</sup> In addition, we were surprised to find that reduction in TEER of the MDCK cells occurred earlier than it did in MDCK-MDR1 cells, which suggests that the TJ barrier in the MDCK-MDR1 was stronger than it was in MDCK, and menthol might have a rapid onset of action in MDCK cells.

Our previous research in rats and mice on the pharmacokinetics of puerarin in Tongqiaosanyu prescription used different methods of administration, including caudal vein injection as well as nasal and oral administration. The study employed reversed-phase high-performance liquid chromatography (RP-HPLC) to determine the concentration of the puerarin in blood and brain tissue samples, which were collected at different time points. Pharmacokinetics in rats showed that  $\text{AUC}_{0\text{e}n}$  following nasal administration was  $376.56 \pm 93.93$  mg/min/L and absolute bioavailability of puerarin was 47.78% by nasal administration, which was significantly higher than oral administration. These results were the basis for our choosing nasal administration of Tongqiaosanyu prescription. Plasma and brain pharmacokinetics in mice indicated that the brain targeting coefficient ( $R_e$ ) was 132.25% following intranasal administration and the brain drug targeting index (DTI) was 2.70, both of which were significantly higher than  $R_e$  and DTI obtained following injection administration. These results showed that intranasal administration enhanced the medicine's penetration and absorption into the brain.<sup>58</sup> Furthermore, we used the abdominal skin of the American bullfrog *Rana catesbeiana* as an in vitro model to study the effect of different concentrations of puerarin and the effect of different proportions of menthol on the apparent perme-

ability coefficient ( $P_{\text{app}}$ ) using the Franz diffusion cell system and HPLC. The results showed there was no significant difference in the effects of different concentrations of puerarin on  $P_{\text{app}}$ , indicating that the permeation of puerarin is via passive diffusion. Furthermore, when the mass concentration of menthol was 5 mg/L, there was a significant difference compared with the puerarin group, which proved that menthol enhanced the permeation of puerarin at a certain concentration range.<sup>59</sup>

The main limitation of this study is that we only explored a single drug dose. Future studies will further investigate the dose-effect relationship. Therefore, the mechanism underlying the effect of drugs on the TJ and transport through the BBB needs further elucidation.

## Conclusion

In conclusion, this preliminary investigation demonstrated the mechanism of puerarin, paeoniflorin, and menthol on TJ proteins and TEER. Compared with puerarin and paeoniflorin, menthol in Tongqiaosanyu prescription affected the TJ structure and function in MDCK and MDCK-MDR1 cells, which were used as in vitro BBB models. Menthol inhibited occludin, claudin-1, and F-actin, which suggests that it may be a potential drug for enhancing the transport of other drugs through the BBB and, thereby, improving their permeation in the brain. Moreover, menthol downregulated the TEER, which verified the relationship between TJ and TEER value, and contributed to opening the barrier to increase paracellular transport. This study was carried out to advance our understanding of the effect of puerarin, paeoniflorin, and menthol on the BBB and provide insight into how Tongqiaosanyu affects TJ structure and function. The study also helps explain the interaction of drugs in a multicomponent herbal prescription.

## References

1. Yliperttula M., Del Amo EM., Urtti A. Influence on pharmacokinetics by L-type amino acid transporters LAT1 and LAT2. *European Journal of Pharmaceutical Science*. 2008;35:161–174.
2. Ohtsuki S, Terasaki T. The blood-brain barrier: a supporting and protective interface for the brain; the role of carrier-mediated transport systems; implications for the development and discovery of drugs for the central nervous system. *Journal of Pharmaceutical Research*, 2007;24:1745–1758. Citation: 3. International Transporter Consortium, Huang SM, Giacomini KM, et al. Membrane transporters in drug development. *The National Journal of Drug Discovery* 2010, 9, 215–236.

The blood-brain barrier: structure and function (Abbott, Patabendige, Dolman, et al., 2004). *Psychobiology of Disease*. 2009;37: 13–25.

3. Vastag M, Keseru GM. Current in vitro and in silico models of blood-brain barrier penetration: a practical perspective. *Drug Discovery and Clinical Practice*. 2009;12:115–124.
- Yang Q, Rager JD, Weinstein K, et al. Assessment of the blood-brain barrier permeability using the MDR-MDCK cell line. *International Journal of Pharmaceutical Sciences*, 2005, 288: 349–359.
7. Decjana E. Endothelial cell-cell junctions: joyous companions. *Natural Reviews in Cell Biology*, 2004, 5, 261–270.
8. Cereijido M, and Anderson JM. *Introduction to Tight Junctions: The Development of Concepts Around Them*. Press, Boca Raton, FL, 2001.
9. Gumbiner B. Overcoming the obstacle of the tight intersection. Jameson et al., 1993, *Journal of Cell Biology*, 123: 1631–1633.
- Yokoyama S, Furuse M, and Itoh M. 10. Strands with several functions bound together in a certain configuration. *Science Translational Medicine*. 2001;2:285–293.
- Eleven. Sawada, Murata, Kikuchi, et al. Human illness and narrow connections. The medical electron microscopy journal published an article in 2003 with the DOI number 36:147–156.
- Schaneeberger EE and Lynch RD. 12. The tight junction is a complex with several functions. *Journal of Applied Physiology and Cell Biology*. 2004;286:1213–1228.
13. Rukkle EA, Mu D. Tight junction proteins: a pathway from cancer to physiological barriers. *Lett. Cancer* 2013;337:41–48. Citation: Collares-Buzato CB, Jepson MA, Simmons NL, Hirst BH. 14. In MDCK epithelia, increased tyrosine phosphorylation disrupts paracellular barrier function and redistributes adherens junction and tight junction proteins. Chapter 15 of the *European Journal of Cell Biology* (Volume 76, Issue 92). Citi S., Rodriguez-Boulan E., Denisenko N., Nigam SK. Cells of cultured renal epithelial (MDCK) play an important part in the formation of tight junctions via phosphorylation. The publication cited is *Biochem Biophys Res Commun*. (1991, 181:548–553). A group of researchers included González-Mariscal, Islas, and Contreras (16). Determination of ZO-1's molecular properties in MDCK cells: a tight junction protein. *Science*. 1999, 248: 97–109.
17. Kim H. Herbs with neuroprotective properties used in traditional Eastern medicine for stroke treatment. *Injectable puerarin for unstable angina pectoris*. *Neurology Research*. 2005;27:287. 18. Wang Q, Wu T, Chen X, et al. Published in Chinese as *Cochrane Database Syst Rev*. 2006;19:4196.
- 19 Wang JW, Cong ZX, and Wang HD. Puerarin reduces oxidative stress after a traumatic brain damage model in rats. *Journal of the American Society for Surgery*, Volume 186, Pages 328–337, 2014.
- Presenting the work of Xia SM, Cheng DY, and Hang XM. An approach to pharmacokinetic investigation including the sensitive liquid chromatography tandem mass spectrometry technique for the detection of paeoniflorin in rat brain has been developed and validated. The citation is from the *Journal of Chromatography, Section B*, volume 857, pages 32–39, 2007.
- Shin MF, Li XM, and Shan QY are the authors of the 21st. Studying the pharmacological effects and chemical compositions of *Mentha Canadensis*. The *Chinese Journal of Traditional Chinese Medicine*, 2012, 7, 1484–1486 [Chinese]. No. 22: Bing Y. Examining the Effects of Tongqiaosan's Effective Constituent on Drug Transport and Compatibility Using a Model of Normal and Oxygen-Glucose Deprivation at the Blood-Brain Barrier [dissertation]. School of Traditional Chinese Medicine in Beijing, China. Section 23: Veszelka, Kittel, and Deli. Tools of simulating blood-brain barrier penetrability. Edited by Tihanyi K and Vastag M. *Drugs and Drug Candidates: Substance Solubility, Administration, and Adverse Drug Reactions*. Publisher: Bentham Science Publishers; Location: Sharjah, United Arab Emirates; Pages: 166–188.
24. Gupta A, Syvaönen S, Hammarlund-Udenaes M, Fride'n M. Regarding the degree and pace of medication distribution to the brain. *Res. in Pharmacology*, 2008, 25, 1737–1750.
- Abbott, Neal, and Patabendige, Akram. Methods for estimating the likelihood that a medicine will penetrate the blood-brain barrier and reach the head. The current medication metabolism journal is *Curr Drug Metab.*, 2008, 9:901; 910.
- Twenty-six. Gumbleton M, Audus KL. Progress and limits in the use of in vitro cell cultures to act as a permeability test for the blood-brain barrier. Published in 2001 in the *Journal of Pharmaceutical Science*, volume 90, pages 1681–1698.
- The correlation between in situ brain permeability and brain free fraction: a study by Summerfield SG, Read K, Begley DJ, and colleagues on drug disposal in the central nervous system. *Scientific Reports*, Volume 322 Issue 1, Pages 205–213,



2007. Reichel A.: The ever-changing new idea of CNS penetration in drug discovery: the fundamentals and consequences. Published in 2009 in the journal *Chem Biodiversity*, volume 6, pages 2030–2049. By Mahar Doan KM, Humphreys JE, Webster LO, and colleagues. Classification of medications for the central nervous system (CNS) and those for the non-CNS is based on passive permeability and efflux mediated by p-glycoprotein. *Journal of Pharmaceutical and Clinical Therapeutics*, 2002, vol. 303, pages 1029–1037. 2. The inhibition and induction of P-glycoprotein mediates drug-drug interactions (Lin JH). *Current Drug Delivery Reviews*. 2003;55:53–81. 30. Authors: Hellinger E, Veszelka S, To'th AE, and others. Brain capillary endothelial cell-based and epithelial cell-based surrogate blood-brain barrier penetration models compared (MDCK-MDR1, Caco-2, and VB-Caco-2). *Euro Journal of Pharmaceutical and Biopharmaceutical Sciences*, 2012, 82, 340–351. 31. Absorption, distribution, and excretion of drugs: the role of transport proteins (Ayrton & Morgan, 2006). Citation: *Xenobiotica*, 2001, 31: 469–497. 32. In the blood-brain barrier, ABC transporters are involved (Miller DS). "Curr Top Med Chem" published a study in 2013 that spanned pages 1295 to 1312. Models of blood-brain barrier penetration based on cells. Vastag M, Hellinger E, Bakk ML, Tihanyi K. —Schulzke JD, Ploeger S, Amasheh M, et al. *Ther Delivery*. 2011;2:549–553. Ligands between epithelial cells during inflammation of the intestines. A claudin-based barrier in both simple and stratified cellular sheets (Tsukita S., Furuse M., *Ann. NY Acad. Sci.* 2009; 1165: 294–300). This article was written by Zahraoui A, Louvard D, and Galli T and was published in the journal *Curr Opin Cell Biol* in 2002. 37. A protein complex trafficking and signalling platform is the tight junction. *Journal of Cell Biology*. 2000; 151: 31–36. 37. Furuse M, Hirase T, Itoh M, et al. A new integral membrane protein called occludin is found in tight junctions. Tsukamoto T, Nigam SK. "Curr Opin Cell Biol." 1993;123:1777–1788. Function of phosphorylated tyrosines in occludin and other tight junction protein reassembly. *I am Journal of Physiology // Cell Chapter 39*: Chen YH, Lu Q, Goodenough DA, Jeansonne B. appeared in *Physiology* (1999, 276:737–750). During the

development of tight junctions in canine kidney epithelial cells, the nonreceptor tyrosine kinase c-yes interacts with occludin. Report from Furuse et al. in *Mol. Biol. Cell*. 2002;13:1227–1237. 40. Two new integral membrane proteins, claudin-1 and -2, that have no sequence resemblance to occludin yet localise to tight junctions. Published in the *Journal of Cell Biology* in 1998, volume 141, pages 1539–1550, the work of Furuse, Sasaki, Fujimoto, and Tsukita delves into this topic. Claudin-1 or -2, a single gene product, attracts occludin to fibroblasts and restores the integrity of tight junction strands. Published in the *Journal of Cell Biology* in 1998, volume 143, pages 391 into 401. The authors of the 42nd article include Kubota, Furuse, Sasaki, and others. Claudins are a class of integral membrane proteins found at tight junctions that have cell-adhesion action that is not reliant on Ca<sup>2+</sup>. Published in the journal *Current Biology*, volume 9, pages 1035–1038, 1999. Andrade KE, Witt KA, 43. Ischemic stroke, blood-brain barrier permeability, and the tight junction. *The Neurobiology of Diseases*. 2008; 32: 200 219. Chapter 44: Shen L., Weber CR., Raleigh DR., Yu D., and Tumer JR. Leak paths and tight junction pores: a dynamic pair. Published in the *Annual Review of Physiology*, 2011;73:283–e309. Rho GTPases and the actin cytoskeleton were discussed by Hall in his 1998 *Science* article (279:112). 42. Ridley AJ, Burridge K, Schwartz MA, et al. Through cell migration, signals are integrated from the front to the rear. The publication is titled "Science" and was published in 2003 with the DOI 3031709. 47. Ivanov AI. Actin proteins that regulate the building and breakdown of apical junctions in epithelial cells. In 2008, the article was published in *Front Bio Sci* with the DOI: 136. 48. Stati S.V. When administered to MDCK epithelial cells, protein kinase inhibitors stop the dissociation of junctions caused by low extracellular calcium. Herrsch M, Noske W. cited in *J Cell Biol*. 1992, 117: 117–169. Structure and function at the tight juncture. *Electron*. 1993;24:325–352. 50. Velarde G, Ait-Aissa S, Gillet C, et al. Examination of pentachlorophenol toxicity by the use of transepithelial electrical resistance. *In Vitro*

Toxicology, 1999, 13, 723–727. McGinn MT and Mullin JM. Diacylglycerol effects on I $\kappa$ B- $\kappa$ 1 renal epithelia: similarities with phorbol ester tumour promoters examined. Gutbiner and Simons (1998) published in the Journal of Cell Physiology, volume 134, pages 357–366. The discovery of an auroreolide-like polypeptide: a functional test for proteins involved in the establishment of an epithelial occluding barrier. Staddon JM, Herrenknecht K, Smales C, and Rubin LL published a paper in the Journal of Cell Biology in 1986, volume 102, pages 436–468. Proof that phosphorylation of tyrosine may enhance the permeability of tight junctions. J Cell Sci. 1995;108:609–619 53. Niessen CM. Adherens junctions and tight junctions: structure and function at a fundamental level. Journal of the American Academy of Dermatology. 2007;127:2525–2532. 54. Turner JR, Buschmann MM, Romero CI, Sailer

A, Shen L. The function of molecular remodelling in the control of tight junction permeability via differential mechanisms. Publication: Semin Cell Dev Biol. 2014;36: 204–212. 55. Ciara CM. The transepithelial electrical resistance of cell layers cultivated on permeable filters may be affected by another factor, cell-substrate interaction. Publication date: 1999 and the volume number: 250, pages 576–580. Number 56: Chen XL, Lu Y, Du SY, Zhao XJ, Li PY. Research comparing the pharmacokinetics of TongqiaoSanyu Formula administered by various routes to the brain and plasma. Journal of Traditional Chinese Medicine, 2014, 29, 2668–2672. From the Chinese language. Authors: Li PY, Lu Y, Du SY, and Cen XL. The in vitro study of puerarin mucosal permeability as it relates to menthol. Chinese Pharmaceutical Journal 2012;23: 4425–4427.